Why Prenetics Global Limited’s (PRE) Stock Is Down 8.30%
As of Friday, July 17, Prenetics Global Limited’s PRE share price has dipped by 8.30%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Prenetics Global Limited (PRE)
Prenetics Global Limited PRE
$18.64
-0.60
-3.12%
July 31, 2026 4:00:00 PM
EST
Volume: 42,540
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Commentary & Analysis
Why Prenetics Global Limited’s (PRE) Stock Is Down 6.97%
As of Thursday, July 16, Prenetics Global Limited’s PRE share price has dipped by 6.97%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Prenetics Global Limited’s (PRE) Stock Is Down 5.27%
As of Wednesday, July 15, Prenetics Global Limited’s PRE share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Prenetics Global Limited’s (PRE) Stock Is Down 14.41%
As of Wednesday, July 15, Prenetics Global Limited’s PRE share price has dipped by 14.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Prenetics Global Limited’s (PRE) Stock Is Up 5.82%
As of Monday, July 13, Prenetics Global Limited’s PRE share price has surged by 5.82%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $323.4 | $1,875.0 | 32% |
|
| Shares Out (Mil) | 16.0 | 77.1 | 27% |
|
| Institutional Ownership | 31.7% | 88.9% | 14% |
|
| Float (Mil) | 12.5 | 50.3 | 22% |
|
| Beta | 0.25 | 0.86 | 15% |
|
| Avg Daily Volume (000s) | 198 | 466 | 45% |
|
| Price Change (52-week) |
140.0% | 78.5% | 95% |
|
| Growth | PRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.2% | 10.9% | 46% |
|
| Net Income (5yr) | (81.8%) | (1.1%) | 3% |
|
| EPS (5yr) | (3.6%) | 3.0% | 26 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.4%) | (18.2%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.775) | ($2.590) | ($0.950) | |
| Month Ago EPS | na | ($2.590) | ($0.680) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.490) | ($1.660) | ($0.680) | |
| Year/Year Chg | 28.7% | 7.1% | (147.1%) | |
| Financials | PRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $92 | $1,464 | 26% |
|
| Net Income (TTM) (Mil) | ($38) | $15 | 19% |
|
| EPS (TTM) | ($2.684) | $0.300 | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | $138 | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $7 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $323 | 14% |
|
| Enterprise Value (Q1) (Mil) | $203 | $2,130 | 26% |
|
| Valuation | PRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.97 | 2.90 | 50% |
|
| P/E | na | 26.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 55.4% | 27.6% | 68% |
|
| Net Margin | (42.0%) | 1.1% | 13% |
|
| ROA | (16.4%) | 1.8% | 22% |
|
| ROE | (20.8%) | 6.9% | 23% |
|
| Liabilities to Assets | 24.1% | 60.0% | 16% |
|
| F-Score | 3 | 5 | na |
|
Prenetics Global Limited did not pass any screens on 7/30/2026.
